Highlights Kaken Pharmaceutical Co., Ltd.

Equities

4521

JP3207000005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
3,407 ^JPY	+0.53%		-0.21%	+1.55%

2023	Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	CI
2023	Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Final dividend	Mar. 27	FA
Kaken Pharmaceutical Co., Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Full Year Ending March 31, 2024	Nov. 14	CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	Nov. 14	CI
Ex-dividend day for interim dividend	23-09-27	FA
Kaken Pharmaceutical’s Attributable Profit Drops 13.7% in Fiscal Q1 due to Higher Expenses	23-08-17	MT
Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024	23-08-17	CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	23-08-17	CI
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	23-06-05	MT
Kaken Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI
Ex-dividend day for final dividend	23-03-29	FA
Cymabay Taps Kaken Pharmaceutical to Develop, Commercialize Liver Disease Drug Candidate in Japan	23-01-09	MT
North American Morning Briefing : Stock Futures Soft as Investors Eye Jobs Report	23-01-06	DJ
Spruce Biosciences, Kaken Sign Licensing Deal for Tildacerfont in Japan; Spruce Shares Surge After Hours	23-01-05	MT
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan	23-01-05	CI
MediWound's Partner Kaken Pharmaceutical Receives Marketing Approval of NexoBrid in Japan, Shares Rise Pre-Bell	22-12-23	MT
MediWound Ltd. Expands NexoBrid’s Global Presence with Marketing Approval in Japan with Kaken Pharmaceutical	22-12-23	CI
Kaken Pharmaceutical to Invest $7 Million in Venture Capital Fund	22-11-09	MT
Ex-dividend day for interim dividend	22-09-28	FA
Tranche Update on Kaken Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	22-07-28	CI
Kaken Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 350,000 shares, representing 0.93% for ¥692.31 million.	22-07-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Kaken Pharmaceutical Co., Ltd.

Equities

4521

JP3207000005

Highlights

Filters